Inhibitor of Differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer

Molecular Endocrinology

Volumn 28, Issue 8, 2014, Pages 1239-1253

  Patel, Divya ^a   Knowell, Ashley E ^a   Korang Yeboah, Maxwell ^b   Sharma, Pankaj ^a   Joshi, Jugal ^a   Glymph, Shanora ^a   Chinaranagari, Swathi ^a   Nagappan, Peri ^a   Palaniappan, Ravi ^b   Bowen, Nathan J ^a   Chaudhary, Jaideep ^a  

^a CLARK ATLANTA UNIVERSITY   (United States)

^b MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF DIFFERENTIATION PROTEIN; INHIBITOR OF DIFFERENTIATION PROTEIN 4; PROSTATE SPECIFIC ANTIGEN; RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ID4 PROTEIN, HUMAN; TESTOSTERONE; TUMOR SUPPRESSOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT; CANCER GROWTH; CARCINOGENICITY; CASTRATION RESISTANT PROSTATE CANCER; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VOLUME; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; RNA ANALYSIS; RNA SEQUENCE; STEROIDOGENESIS; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; DISEASE FREE SURVIVAL; HUMAN; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TESTOSTERONE; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS;

EID: 84905237800     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1100     Document Type: Article

References (52)

1. Wang J, Shang ZQ, Niu YJ. Androgen receptor roles in benign and malignant prostate disease. Clin Oncol Cancer Res. 2011;8: 85-91.
2. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010;21:315-324.
3. Kobayashi T, Inoue T, Kamba T, Ogawa O. Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci. 2013;14:15615-15635.
4. Riechmann V, van Crüchten I, Sablitzky F. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res. 1994;22: 749-755.
5. Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet. 2005;37: 265-274.
6. Chen SS, Claus R, Lucas DM, et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood. 2011;117:862-871.
7. Chan AS, Tsui WY, Chen X, et al. Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene. 2003;22:6946-6953.
8. Castro M, Grau L, Puerta P, et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. 2010;8:86.
9. Sharma P, Chinaranagari S, Patel D, Carey J, Chaudhary J. Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer. Cancer Med. 2012;1:176-186.
10. Sharma P, Knowell AE, Chinaranagari S, et al. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN. Mol Cancer. 2013;12:67.
11. Vinarskaja A, Goering W, Ingenwerth M, Schulz WA. ID4 is frequently downregulated and partially hypermethylated in prostate cancer. World J Urol. 2012;30:319-325.
12. Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer. 2009;9:173.
13. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate. 2002;50:222-235.
14. Knowell A, Patel D, Morton D, Sharma P, Glymph S, Chaudhary J. Id4 dependent acetylation restores mutant-p53 transcriptional activity. Mol Cancer. 2013;12:161.
15. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF. Expression of human prostatic acid phosphatase correlates with androgen- stimulated cell proliferation in prostate cancer cell lines. J Biol Chem. 1998;273:5939-5947.
16. Walker L, Millena AC, Strong N, Khan SA. Expression of TGFβ3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway. Clin Exp Metastasis. 2013;30:13-23.
17. Sharma P, Patel D, Chaudhary J. Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B. Cancer Med. 2012;1:187-197.
18. Asirvatham AJ, Schmidt MA, Chaudhary J. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells. Prostate. 2006;66:921-935.
19. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14: R36.
20. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol. 2013;31:46-53.
21. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-675.
22. Goldman M, Craft B, Swatloski T, et al. The UCSC Cancer Genomics Browser: update 2013. Nucleic Acids Res. 2013;41(Database issue):D949-D954.
23. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
24. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-404.
25. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:p l1.
26. Tamura K, Furihata M, Tsunoda T, et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 2007;67:5117-5125.
27. Venanzoni MC, Giunta S, Muraro GB, et al. Apolipoprotein E expression in localized prostate cancers. Int J Oncol. 2003;22:779-786.
28. Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors. Cell Cycle. 2010;9: 2342-2352.
29. Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003;13:410-418.
30. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 2001;61:2736-2743.
31. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16INK4a/pRB pathway. Carcinogenesis. 2002;23:721-725.
32. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 1999;401:670-677.
33. Ling MT, Lau TC, Zhou C, et al. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis. 2005;26: 1668-1676.
34. Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol. 2008;295: 115-120.
35. Takeda H, Nakamoto T, Kokontis J, Chodak GW, Chang C. Autoregulation of androgen receptor expression in rodent prostate: Immunohistochemical and in situ hybridization analysis. Biochem Biophys Res Commun. 1991;177:488-496.
36. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999;13: 966-977.
37. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology. 2003;144:1656-1663.
38. Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt G, Pousette A. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. Oncol Rep. 2004;11:1187-1192.
39. Ling MT, Wang X, Lee DT, Tam PC, Tsao SW, Wong YC. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis. 2004;25:517-525.
40. Ling MT, Wang X, Ouyang XS, et al. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene. 2002;21:8498-8505.
41. Coppe JP, Itahana Y, Moore DH, Bennington JL, Desprez PY. Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res. 2004;10:2044-2051.
42. Prabhu S, Ignatova A, Park ST, Sun XH. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol. 1997;17:5888-5896.
43. Andersen RJ, Mawji NR, Wang J, et al. Regression of castraterecurrent prostate cancer by a small-molecule inhibitor of the amino- terminus domain of the androgen receptor. Cancer Cell. 2010; 17:535-546.
44. Lai KP, Huang CK, Chang YJ, Chung CY, et al. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013;182:460-473.
45. Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME, Guns ES. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol. 2009;115: 126-136.
46. Tran C, Ouk S, Clegg NJ, et al. Development of a second-genera- tion antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787-790.
47. Carnell AJ, Kirk R, Smith M, McKenna S, Lian LY, Gibson R. Inhibition of human α-methylacyl CoA racemase (AMACR): a target for prostate cancer [published online ahead of print August 8, 2013]. ChemMedChem. 2013. doi: 10.1002/cmdc.201300179.
48. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22:2790-2799.
49. Chowdhury UR, Samant RS, Fodstad O, Shevde LA. Emerging role of nuclear protein 1 (NUPR1) in cancer biology. Cancer Metastasis Rev. 2009;28:225-232.
50. Song Y, Oda Y, Hori M, et al. N-myc downstream regulated gene- 1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin. Hum Pathol. 2010;41:214-222.
51. Dahlman A, Edsjö A, Halldén C, et al. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis. 2010;13:369-375.
52. Wang Q, Williamson M, Bott S, Brookman-Amissah N, et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene. 2007;26:6560-6565.